Download by
Scanning QR Code
No Stock Yet
Hysen Pharmaceutical's IPO faces torture: collection failed, it's not easy to go overseas, and environmental protection has been punished
“Investor Network” Cai Jun went to Taizhou from Dongyang, Zhejiang, to gather countless API and CRO companies, spawned many listed companies, and many are sprinting for IPOs. In February of this year, Zhejiang Hysen Pharmaceutical Co., Ltd. (hereinafter referred to as “Hysen Pharmaceutical”, the “Company”) from Dongyang updated its prospectus. The company plans to list on the main board of the Shenzhen Stock Exchange and is expected to raise more than 600 million yuan to be used for production lines, R&D centers and office buildings, supplementary working capital, etc. Previously, the Securities Regulatory Commission gave feedback on issues such as environmental protection and sales expenses, and Hysen Pharmaceutical responded in the updated prospectus. In terms of business model, the company mainly produces orders from large customers.
Lepu Healthcare (300003.SZ) granted 2.273,500 restricted shares at a price of 10.74 yuan/share
According to the Zhitong Finance App, Lepu Healthcare (300003.SZ) announced that the grant conditions stipulated in the company's 2022 restricted stock incentive plan have all been met. The company will use December 30, 2022 as the restricted stock reserve grant date, and will grant 2.273,500 restricted shares to 150 incentive recipients who meet the grant conditions at a grant price of 10.74 yuan/share.
Changes in A-shares | Medical device stocks strengthen, many models of oximeters are out of stock+price increases
Gelonghui, December 26, 丨 Medical device stocks strengthened, Kangtai Medical rose 5%, ST Oriental and Kerfu Medical rose 4%, and Yuyue Medical and Lepu Medical rose 3%. According to the news, oximeters are facing challenges such as lack of stock, long pre-sale times, and price increases. A recent search of major e-commerce platforms revealed that currently only a few stores can place orders for oximeters that can be shipped immediately. Most stores have sold out multiple models of oximeters. Some models are on pre-sale, and delivery times range from 2 to 15 days. As investors, I called a number of listed companies that set up oximetry business. A number of companies said that demand for oximetry products is currently tight.
Concept Tracker | Supply is outstripping demand! Oximeters have become yet another company related to epidemic prevention products that are out of stock and that they have begun to produce them at full capacity (concept stock included)
The Zhitong Finance App learned that recently, after N95 masks, ibuprofen, and antigen detection reagents, a finger clip oximeter for COVID-19 protective equipment is also popular. According to reports, on platforms such as Taobao and Jingdong, finger clip oximeters are currently in short supply in the official flagship stores of major brands such as Yuyue Medical (002223.SZ), Kangtai Medical (300869.SZ), and Omron. Many models are out of stock and have entered the pre-sale mode. In response, many listed medical device companies have indicated that they are currently producing at full capacity to guarantee the supply of oximetry products. Related concept stocks: Kangtai Medical (300869.
PricewaterhouseCoopers (01358) and Lepp Medical enter into a framework agreement to purchase medical device molds and components
According to the Zhitong Finance App, Prudential Heshun (01358) announced that on December 14, 2022 (after the trading period), the company signed a framework agreement with Lepu Medical to purchase medical device molds and components. According to this, the group agreed to purchase medical device molds and components from Lepu Medical Group, including but not limited to molds, end caps, support rings, sealing rings, sealing rings, pipes and other components for blood purification products. The period will run from December 14, 2022 to December 31, 2023, and may be repeated according to the listing rules after mutual agreement between the contracting parties.
Huatai Securities: COVID-19 antigen application plan released, highlighting the importance of antigen self-testing under optimization of prevention and control
The Zhitong Finance App learned that Huatai Securities released a research report saying that on December 7, the State Council Joint Prevention and Control Mechanism Comprehensive Team in Response to the COVID-19 Epidemic issued the “Coronavirus Antigen Testing Application Plan”. The bank believes that the publication of the plan has once again strengthened the important role of antigen self-testing in the new stage of domestic epidemic prevention and control optimization. It is recommended to pay attention to relevant manufacturers with products, certification, and production capacity. Companies related to the industry chain include Oriental Biology (688298.SH), Lepu Medical (300003.SZ), Matilda Biology (002932.SZ), Hot Scene Biology (688068.SH), Aotai
Changes in A-shares | Lepu Medical rose 4% Antigen kits “in short supply”
Glonhui, December 9丨Lepu Healthcare (300003.SZ) rose 4.65% to 23.87 yuan, with a total market capitalization of 44.9 billion yuan. Yesterday, a notice from Lepu Diagnostic Technology came out on the Internet, showing that after receiving a phone call from the Beijing Drug Administration, all antigen kits will be collected today and tomorrow. In response, the company stated that it had not issued the above notice before, nor had it received a related phone call. Regarding the current production and delivery situation, the company also indicated that it is currently in order status and is not in stock. There were a lot of orders, but it was too late for delivery. In addition, the company said that production capacity will be dynamic according to factors such as the development of the epidemic and market conditions
Lepu Healthcare: Antigen kits are “in short supply”, currently only ordered and not in stock to be distributed
Glonhui, December 8丨According to Yicai, a notice from Lepu Diagnostic Technology came out on the Internet yesterday showing that after receiving a phone call from the Beijing Drug Administration, all antigen kits will be collected today and tomorrow. In response, today, the reporter called the Lepu Healthcare Investor Hotline as an investor. The company said that it had not issued the above notice before, nor had it received any related phone calls. Regarding the current production and delivery situation, the company also indicated that it is currently in order status and is not in stock. There were a lot of orders, but it was too late for delivery. In addition, the company said that production capacity will be dynamically adjusted according to factors such as the development of the epidemic and market conditions, and adjusted in a timely manner according to market demand
Lepu Healthcare split two subsidiaries and Lepu's COVID-19 antigen diagnosis business declined markedly
Wu Yue, editor of “Investor Network” Cai Jun, by the end of November this year, Lepu (Beijing) Medical Devices Co., Ltd. (300003.SZ, “Lepu Medical”, hereinafter referred to as “Lepu Medical”) had split two subsidiaries and went public. In the first three quarters of this year, Lepu Medical achieved operating income of 7.762 billion yuan, a year-on-year decrease of 10.11%, and net profit attributable to shareholders of listed companies was 1.81 billion yuan, a year-on-year decrease of 5.78%. In response, Lepu Medical said that the decline in performance was due to the high revenue base of COVID-19 antigen detection reagents in 2021, and the business's revenue fell 77% year-on-year; if the influence of related factors was excluded, regular business
Lepu Medical: one-time use of pressure microcatheter to obtain product registration certificate.
Loading...
No Stock Yet